Backs FY25 revenue view 4.53B yen. Backs FY25 adjusted free cash flow view 750 yen-850 yen.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TAK:
- Alkermes selling off on limited data disclosure, says BofA
- Takeda receives FDA clearance for HyHub, HyHub Duo
- Avidity, Phathom mentioned as potential takeout targets at Needham
- Keros Therapeutics announces first patient dosed in Phase 3 RENEW trial
- Buy Rating for Takeda Pharmaceutical Driven by Successful Phase 3 Trials of Oveporexton